New Research Publication: OliFuco® Oligo Fucoidan as an Adjunct Therapy for Lung Cancer

IHi-Q is pleased to announce the publication of our study investigating the use of OliFuco® Oligo Fucoidan, our proprietary ingredient, as an adjunct therapy for lung cancer. Given lung cancer’s high incidence and mortality rates, particularly in Taiwan, our research focused on evaluating how adding OliFuco® to conventional treatments could impact patient outcomes.

Study Overview:

Participants: NSCLC patients aged 20-80.

Groups: Control (conventional therapy) vs. OliFuco® group (conventional therapy + oral supplementation of OliFuco®).

Duration: Data collected at baseline, weeks 4, 12, and 24.

Key Findings:

Survival Rates: The OliFuco® group showed improved survival rates compared to the control group.

Quality of Life: The OliFuco® group exhibited a trend towards a better quality of life compared to the control group.

Immune Function: Patients receiving OliFuco® showed an increased CD19 lymphocyte population and reduced levels of inflammatory cytokines.

Conclusion:

The publication highlights OliFuco® Oligo Fucoidan’s potential as an effective adjunct therapy to enhance conventional lung cancer treatments. By improving survival rates, quality of life, and immune function, OliFuco® offers a promising complement to existing therapies.

We are grateful to all who contributed to this important research. For a comprehensive look at the study, please check out the full publication! https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227263/

#taiwan #hiq #hiqmarinebiotech

#fucoidan #fucoidaningredient #ingredient

#LowMolecularWeightFucoidan #fucohiq

#oligofucoidan #olifuco #oncofuco

#AdjunctNutritionalSupport #clinicaltrial #lungcancer #NonSmallCellLungCancer #NSCLC

Back